MedTrace Logo

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce

NCT05216172 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-06-20

No results posted yet for this study

Summary

AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce: a single site, placebo-controlled, double-blind randomised clinical trial of AZD1656 in renal transplant patients with Type 2 diabetes

Conditions

Interventions

DRUG

AZD1656

active drug

DRUG

Placebo

placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Kieran McCafferty, M.B., B.Chir · Barts Health NHS Trust; Queen Mary University London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-13
Primary Completion
2022-09-11
Completion
2022-09-11

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05216172 on ClinicalTrials.gov